K.N. Chi

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

K.N. Chi, Thian Kheoh, Charles J. Ryan et al. · Annals of Oncology · 2015 · 165 citations · Full text

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Oliver Sartor, D.E. Castellano Gauna, Ken Herrmann et al. · Annals of Oncology · 2023 · 66 citations · Full text

Urology, Genitourinary Cancer, Medicine +6

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)

C. Kollmannsberger, Hal W. Hirte, Lillian L. Siu et al. · Annals of Oncology · 2011 · 39 citations · Full text

Open-label Dose-escalation Study, Medicine, Metronomic Therapy +10

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

K.N. Chi, E. Beardsley, Bernhard J. Eigl et al. · Annals of Oncology · 2011 · 36 citations · Full text

Urological Research, Urology, Genitourinary Cancer +6

LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

K.N. Chi, Elena Castro, Gerhardt Attard et al. · Annals of Oncology · 2023 · 12 citations · Full text

Urology, Gene Alterations, Genitourinary Cancer +8